Cero Therapeutics Holdings, INC Form 4 insider transactions

Brian G. Atwood, a director of Cero Therapeutics Holdings, acquired pre-funded warrants and warrants to purchase common stock on February 7, 2025.

YK Bioventures Opportunities Fund I, L.P. sold a significant portion of its Cero Therapeutics Holdings stock over three days, reducing its holdings from 17.6 million to 13 million shares.

YK Bioventures Opportunities Fund I, L.P. sold a significant number of Cero Therapeutics shares over several days in December 2024.

Cero Therapeutics CEO Christopher B. Ehrlich exercised options for 1,275,000 shares after performance criteria were met.

Director Lindsey Rolfe exercised stock options for 127,500 shares of Cero Therapeutics after performance criteria were met.

Kathleen Laporte, a director at Cero Therapeutics Holdings, exercised stock options for 127,500 shares after performance criteria were met.

A Cero Therapeutics director, Michael Byrnes, exercised stock options for 127,500 shares after performance criteria were met.

Brian G. Atwood, a director at Cero Therapeutics Holdings, Inc., acquired 254,000 shares of common stock through the vesting of a stock option.

A Cero Therapeutics director, Shami Patel, exercised stock options for 127,500 shares after performance criteria were met.

Stuart Sloan, a director of Cero Therapeutics Holdings, acquired 532,486 shares of common stock at an average price of $0.1043 per share.

YK Bioventures Opportunities Fund I, L.P. sold 3,250,000 shares of Cero Therapeutics Holdings, Inc. at an average price of $0.10 per share.

Kathleen LaPorte, a director of Cero Therapeutics Holdings, converted 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock on September 25, 2024.

Christopher B. Ehrlich, Interim Chairman and CEO of Cero Therapeutics Holdings, converted Series A Preferred Stock into common stock and forfeited employee stock options.

Director Brian Atwood converted Series A Preferred Stock into common stock and forfeited employee stock options following his resignation as CEO.

Andrew Kucharckuk, CFO of Cero Therapeutics Holdings, Inc., reports the acquisition of 500,000 stock options.

Kristen Pierce, Chief Development Officer of Cero Therapeutics Holdings, Inc., acquired stock options for 200,000 shares on October 1, 2024.

Charles Ross Carter, CFO of Cero Therapeutics Holdings, Inc., was granted stock options contingent upon FDA acceptance of an Investigational New Drug application.

Lindsey Rolfe, a director at Cero Therapeutics Holdings, acquired stock options for 112,500 shares on March 25, 2024.

Director Robyn Rapaport acquired stock options for 112,500 shares of Cero Therapeutics Holdings, Inc. at an exercise price of $1.77 on March 25, 2024.

Kathleen Laporte, a director of Cero Therapeutics Holdings, acquired stock options exercisable for 112,500 shares of common stock on March 25, 2024.

Christopher B. Ehrlich, a director at Cero Therapeutics Holdings, acquired stock options for 572,182 shares on March 25, 2024.

Daniel Corey, Chief Technical Officer of Cero Therapeutics Holdings, Inc., acquired stock options for 856,671 shares on March 25, 2024.

Charles Ross Carter, CFO of Cero Therapeutics Holdings, Inc., acquired stock options on March 25, 2024.

Director Michael Byrnes acquired stock options in Cero Therapeutics Holdings, Inc. on March 25, 2024.

Brian G. Atwood, CEO of Cero Therapeutics Holdings, acquired stock options for 1,317,956 shares on March 25, 2024.

Brian Atwood, CEO of CERO Therapeutics Holdings, files an amended Form 4 to include previously omitted stock options in his beneficial ownership disclosure following the company's recent business combination.